Important Note This article is for educational purposes only. BPC-157 is an investigational compound and is not approved for human use in the United Kingdom or most other countries. This content does not constitute medical advice.
BPC-157 (Body Protection Compound-157) is a synthetic peptide that has been studied primarily for its potential effects on tissue healing and protection. Most of the available research comes from animal studies and laboratory experiments rather than large-scale human clinical trials.
This page provides a clear summary of what current research shows regarding BPC-157 in relation to tissue healing.
What Is BPC-157?
BPC-157 is a synthetic peptide consisting of 15 amino acids. It was originally derived from a protein found in human gastric juice. Researchers initially explored its potential protective effects on the digestive system, but later expanded their investigations to include its possible role in healing tendons, ligaments, muscles, and other tissues.
Areas of Research on Tissue Healing
Most studies on BPC-157 and tissue healing have been conducted in animal models (primarily rats and mice). Key areas of research include:
Tendon and Ligament Healing Some animal studies have suggested that BPC-157 may accelerate the healing of injured tendons and ligaments. Researchers have observed improvements in tissue structure and mechanical strength in certain models.
Muscle Injury and Recovery Research has explored whether BPC-157 may support healing after muscle strain or trauma. Some studies in animals have reported faster recovery and reduced inflammation following administration.
Gastrointestinal Healing Because of its origin in gastric juice, several studies have examined BPC-157’s potential protective and reparative effects on the lining of the stomach and intestines in animal models of injury or inflammation.
Blood Vessel Formation (Angiogenesis) Some research has investigated whether BPC-157 may influence the formation of new blood vessels, which plays an important role in the healing process.
Current Limitations of the Research
Despite interesting findings in animal studies, several important limitations exist:
- Most data comes from animal research rather than human clinical trials.
- The exact mechanisms of action are not fully understood.
- There is currently no strong clinical evidence supporting its use in humans.
- Long-term safety data in humans is lacking.
- BPC-157 remains an investigational compound and is not approved by the MHRA or other major regulatory bodies.
Why Researchers Continue to Study BPC-157
BPC-157 continues to attract research interest for several reasons:
- It is relatively simple to synthesise.
- Early animal studies have shown interesting effects on tissue repair.
- It is derived from a protein that naturally occurs in the human body.
However, scientific interest alone does not confirm safety or effectiveness in humans. Many compounds show promise in early research but do not progress further due to inconsistent results, safety concerns, or insufficient clinical evidence.
Summary
BPC-157 is a synthetic peptide that has been studied mainly in animal models for its potential effects on tissue healing, particularly in tendons, muscles, and the gastrointestinal tract. While some early research has shown interesting results, high-quality human clinical trial data remains limited. As of 2026, BPC-157 is not approved for human use in the UK and continues to be regarded as an investigational compound. More rigorous human studies are needed to better understand its potential effects and safety profile.You can explore research peptide options on PeptidesX.uk
References
- Sikiric, P. et al. (2010). Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Current Pharmaceutical Design.
- Sikiric, P. et al. (2018). BPC 157 and standard angiogenic growth factors in tendon healing. Journal of Orthopaedic Research.
- Krivic, A. et al. (2005). Achilles detachment in rat and stable gastric pentadecapeptide BPC 157: Promoted tendon-to-bone healing and opposed corticosteroid aggravation. Journal of Orthopaedic Research.
- ClinicalTrials.gov – Limited human trials registered for BPC-157 as of 2026.
- Medicines and Healthcare products Regulatory Agency (MHRA) – Position on unlicensed substances.
For more context, read our main guide on BPC-157 Research
Last Updated: July 2026